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Objectives: (S)-Leucoxine, isolated from the Colombian Lauraceae tree Rhodostemonodaphne crenaticupula
Madrin˜an, was found to inhibit the growth of Mycobacterium tuberculosis H37Rv. A biomimetic approach for
the chemical synthesis of a wide array of 1-substituted tetrahydroisoquinolines was undertaken with the aim
of elucidating a common pharmacophore for these compounds with novel mode(s) of anti-TB action.
Methods: Biomimetic Pictet–Spengler or Bischler–Napieralski synthetic routes were employed followed by an
evaluation of the biological activity of the synthesized compounds.
Results: In this work, the synthesized tetrahydroisoquinolines were found to inhibit the growth of M. tuberculosis
H37Rv and affect its whole-cell phenotype as well as the activity of the ATP-dependent MurE ligase, a key enzyme
involved in the early stage of cell wall peptidoglycan biosynthesis.
Conclusions: As the correlation between the MIC and the half-inhibitory enzymatic concentration was not
particularly strong, there is a credible possibility that these compounds have pleiotropic mechanism(s) of action
in M. tuberculosis.
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Introduction
TB has been a scourge of humanity for millennia and continues to
elude many concerted efforts towards its eradication. According to
the latest figures from the WHO, 8.6 million people developed the
disease in 2012, and 1.3 million people died from it.1 Incidences
of XDR strains of the TB-causing pathogen Mycobacterium tubercu-
losis are increasing across all inhabited continents and there have
been reports of totally drug-resistant strains from India, which
has intensified the alarm worldwide.2 Infection with these strains
is virtually impossible to treat, and particularly in immune-
compromised individuals it is almost always a sentence of death.3
It is therefore imperative that new anti-TB drugs with novel mode(s)
of action are discovered in order to reduce the length of treatment
and decimate the resistant strains.
Alkaloids are among the most biologically active plant phyto-
constituents. Powerful activities have been described for several
alkaloids (tubocurarine, colchicine, camptothecin, quinine and
pilocarpine among many others) and some of these scaffolds
may still prove useful in new therapeutic areas. Anti-TB alkaloids
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were the subject of a review in 2009,4 and the interest in natural
nitrogen-containing compounds for selective TB treatment has
since seen a resurgence.5 – 8 The hirsutellone and manzamine
classes are some of the most attractive anti-TB alkaloids, display-
ing high potency and selectivity.9,10 The tetrahydroisoquinoline
(THI) alkaloid, a noraporphine, extracted from the Colombian
tree Ocotea macrophylla Kunth, shares structural similarity with
other reported anti-TB THIs such as cepharadione B, piperolactam
A and (2)-nordicentrine.11,12 It has demonstrated antimycobac-
terial specific activity as well as M. tuberculosis MurE (Mtb-MurE)
inhibition.13
The ATP-dependent Mur ligases (also known as Mur synthetases)
are a set of four enzymes Mur C, D, E and F that sequentially add four
amino acids: L-alanine (L-Ala), D-glutamic acid (D-Glu), meso-
diaminopimelic acid (m-DAP) and the dipeptide D-alanine-D-alanine
(D-Ala-D-Ala) to UDP-MurNAc, resulting in the formation of a precur-
sor of cell wall peptidoglycan (PG). PG is the basal mesh that cova-
lently supports the mycolyl-arabinogalactan unit of the cell wall core;
therefore, by targeting the biosynthesis of this macromolecule, the
stability of the cell wall would be disrupted, affecting the viability
of the mycobacteria.
The genes encoding the Mur synthetases, which are absent in
eukaryotic cells, have been demonstrated to be essential for the
growth and viability of a wide number of bacterial species14
including M. tuberculosis15 and are conserved in all the bacterial
pathogens16 including the genetically decayed, obligatory
human pathogen Mycobacterium leprae.17 The Mur synthetases
from M. tuberculosis have been characterized biochemically and
structurally over the past few years by our research group18 – 20
and, through chemical inhibition, have been validated as potential
therapeutic targets.13,21,22 They contain accessible active sites for
drugs or inhibitors to bind to and as yet have not been reported as
targets for any of the currently available drugs on the market,
making them attractive targets for novel therapeutic entities
such as THIs.
THIs are often prepared via the coupling of phenethylamines
with carboxylic acids and subsequent Bischler–Napieralski cyclo-
dehydration and reduction.23 This strategy, however, requires the
protection of hydroxy and amino groups, burdening the synthetic
route with rather a large number of steps. We have recently devel-
oped biomimetic reaction conditions for the Pictet–Spengler con-
densation of aldehydes and amines into THIs.24 In contrast to the
Bischler–Napieralski approach, the biomimetic Pictet–Spengler
condensation has only one step and does not require the use of
protecting groups. The reaction is mediated by phosphate and is
performed under mild reaction conditions (pH 6, 508C) that are
suitable for a variety of less stable or oxidatively sensitive alde-
hyde and amine substrates.
Building on knowledge of the previously reported THIs, screening
the chemical space of substituted THIs could help to elucidate a
common anti-TB pharmacophore. The strategy undertaken in this
investigation was to screen natural and synthetic 1-substituted
isoquinolines against Mycobacterium bovis BCG. Active hits were
confirmed against M. tuberculosis H37Rv and their cytotoxicity
was surveyed against a murine macrophage (RAW 264.7) cell
line. Antibacterial specificity was determined by evaluating the
selected compounds against other bacterial species. We previously
found that this class of molecules inhibits the MurE ligase of
M. tuberculosis and therefore their enzymatic inhibitory effect on
Mtb-MurE was also explored.
Materials and methods
Bacterial strains, cell lines and culture media
The bacterial species used in this study were M. tuberculosis H37Rv (ATTC
27294), M. bovis BCG Pasteur (ATCC 35734), Mycobacterium aurum (ATCC
23366), Mycobacterium smegmatis mc2155 (ATCC 700084), Rhodococcus
equi RHA1, Escherichia coli JM109 (ATCC 53323) and Pseudomonas putida
(ATCC 12633). The mammalian cell line for assessing cytotoxicity was the
murine macrophage cell line RAW264.7 (ATCC TIB-71). Mycobacteria were cul-
tured in Middlebrook 7H9 broth or Middlebrook 7H10 agar media supplemen-
ted with albumin/dextrose/catalase (ADC) or oleic acid/albumin/dextrose/
catalase (OADC) enrichments, respectively. These supplements were pur-
chased from BD Biosciences. All other bacteria were grown in LB broth or
agar. Reagents were purchased from Sigma-Aldrich unless stated otherwise.
Isolation of (S)-leucoxine
Rhodostemonodaphne crenaticupula Madrin˜an was collected in January
2010 near the Duitama-Charala´ road (Department of Boyaca´, Colombia).
A voucher specimen (COL 544558) was deposited at the Herbario
Nacional Colombiano, Universidad Nacional de Colombia. Dried and pow-
dered leaves (810 g) of R. crenaticupula were macerated with ethanol at
room temperature (258C). The ethanolic extract was concentrated under
reduced pressure (60 g), and fractioned by soxhlet with petroleum ether,
chloroform and methanol. The chloroform extract was fractioned by vac-
uum LC eluting with toluene/isopropyl acetate mixtures (8:2 to 1:9) afford-
ing 36 fractions. Fractions 3–11 showed a precipitate that was recovered by
decantation and purified by Sephadex LH-20 column chromatography elut-
ing with methanol to yield compound 1. NMR spectra for 1H (400 MHz), 13C
(100 MHz), and 2D [correlation spectroscopy (COSY), heteronuclear multiple
bond correlation (HMBC) and heteronuclear multiple quantum correlation
(HMQC)] were recorded at 298 K using a Bruker Avance 400 spectrometer.
High-resolution MS spectra were acquired using a TOF system (Waters LCT
Premier XE) operated in positive mode. Optical rotations were measured
using a Bellingham and Stanley ADP440+ digital polarimeter. The detailed
spectroscopic data are available as Supplementary data at JAC Online.
Methodology for synthesis
All reagents were obtained from commercial sources and used as received
unless otherwise stated. TLC was performed on Kieselgel 60 F254 pre-
coated plastic plates, and compounds were visualized by exposure to UV
light, potassium permanganate, phosphomolybdic acid or ninhydrin. Flash
column chromatography was carried out using silica gel (particle size 40–
63 mm). Both analytical and preparative HPLC were performed on a Varian
ProStar machine equipped with an autosampler, a UV-visible detector and
a Discovery BIO Wide Pore C18-10 Supelco column (25×0.46 cm for ana-
lytical scale work and 25×2.12 cm for preparative scale work). Elutions
were monitored at 280 nm and carried out according to either of the fol-
lowing gradients: gradient 1, 5% to 40% of acetonitrile/water (0.1% tri-
fluoroacetic acid or TFA); gradient 2, 5% to 90% of acetonitrile/water
(0.1% TFA). NMR spectra for 1H and 13C were recorded at 298 K at the
field indicated using Bruker AMX 300, AMX 400, Avance 500 and Avance
600 machines. Coupling constants were measured in Hertz and referenced
to the deuterated solvent used. Infrared spectra were recorded on a
PerkinElmer Spectrum 100 FT-IR spectrometer. Optical rotations were
recorded on a PerkinElmer model 343 Polarimeter at 589 nm. Mass spectra
were recorded on Thermo Finnegan MAT 900XP and Micro Mass Quattro LC
electrospray mass spectrometers VG ZAB 2SE. Compounds 2–16 were
synthesized as previously described.24
General procedure A (biomimetic Pictet–Spengler reaction)
The amine (1.0 eq.) and aldehyde (1.2 eq.) were added to 10 mL of a 1:1
mixture of acetonitrile/dipotassium phosphate buffer (0.1 M solution at pH 6).
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The resulting solution was stirred at 508C for 12 h. The crude product was
concentrated under reduced pressure and purified by preparative HPLC
(either gradient 1 or gradient 2), and fractions containing the desired
product were combined, concentrated and co-evaporated with methanol
(3×20 mL).
General procedure B (Bischler–Napieralski cyclization
and reduction)
The reaction was carried out under anhydrous conditions. Phosphorous
oxychloride (10 eq.) and molecular sieves were added to a solution of
the amide (1.0 eq.) in anhydrous toluene (10 mL). The reaction mixture
was heated at reflux for 2 h, cooled to room temperature (RT) and concen-
trated under reduced pressure. To the crude material were added
NaBH3CN (5 eq.), molecular sieves and anhydrous methanol (10 mL),
and the reaction was stirred under an inert atmosphere for 2 h. The solvent
was then removed in vacuo and the product purified using HPLC, either gra-
dient 1 or gradient 2. Fractions containing the desired product were com-
bined, concentrated and co-evaporated with methanol (3×20 mL).
Detailed synthetic protocols for compounds 17–40 and spectroscopic
data are available as Supplementary data.
Evaluation of antibacterial properties
Mycobacterial growth inhibitory activities were examined using the spot
culture growth inhibition (SPOTi) assay as previously described.25,26 All
compounds were dissolved in DMSO at 100 g/L. The assays were per-
formed in a 24-well format in which 2 mL of various dilutions of the com-
pounds were dissolved in 2 mL of Middlebrook 7H10 agar media
supplemented with 0.25% glycerol and 10% OADC. A volume of 2 mL of
a mid-logarithmic phase culture ( 106 cfu/mL) of M. tuberculosis H37Rv,
M. bovis BCG Pasteur, M. aurum or M. smegmatis mc2155 grown in
Middlebrook 7H9 broth media supplemented with 0.2% glycerol, 0.05%
Tween 80 and 10% ADC was added to each well, and the plates were
then incubated for 2 weeks at 378C. The MIC was determined as the min-
imum concentration of the compounds that completely prevented myco-
bacterial growth. Isoniazid and rifampicin were used as positive controls
and 0.1% DMSO was used as a negative control. The SPOTi assay was per-
formed against E. coli, P. putida and R. equi RHA1 as described, except that
LB broth and LB agar were used as growth media. E. coli and P. putida were
grown at 378C overnight, while R. equi RHA1 was grown at 308C for 48 h.
Assaying eukaryotic cell toxicity
The murine macrophage cell line RAW264.7 was cultured and maintained
as previously described27 and the cytotoxicity assay was conducted as
previously reported.28 Half-growth-inhibitory concentrations (GIC50s)
were determined by interpolation based on the viability percentage com-
pared with control experiments. Selectivity index (SI) values were calcu-
lated by dividing the macrophage GIC50 values by the mycobacterial MIC
values.
Pharmacokinetic and pharmacodynamic properties
of THIs
Compounds 28 and 35were assessed on various parameters to determine
their potential for progress into further drug development. The following
assays were contracted to and performed at Pharmidex, UK and detailed
results are provided in the Supplementary data.
Human hepatocyte stability assay
The compounds originally dissolved in DMSO were added to PBS to give a
resulting concentration of 1 mM. Hepatocytes were then added to the
solution and the reaction was incubated at 378C for up to 120 min.
Acetonitrile with internal standard was added to stop the incubation.
The samples were centrifuged and the supernatant was then analysed
by HPLC-MS/MS to detect the parent compound.
Aqueous kinetic solubility
Aqueous kinetic solubility was measured at concentrations of 1 and
0.1 mg/mL. The compounds were equilibrated in 5% DMSO in PBS
at 218C for 24 h. The samples were then centrifuged at 15000 g for
10 min. A 100 mL sample of the supernatant was carefully collected and
the soluble amount of compound quantified using LC-MS/MS. A standard
curve for each compound was prepared in 100% acetonitrile. Solubility
results are reported as low (,0.1 mg/mL), medium (0.1–0.5 mg/mL)
and high (.0.5 mg/mL).
Human microsome stability assay
The compounds originally dissolved in DMSO were added to PBS to give a
resulting concentration of 1 mM. Microsomes and NADPH were then added
to the solution and the reaction was incubated at 378C for up to 60 min.
Acetonitrile (300 mL) with internal standard was added to stop the
incubation. The samples were centrifuged and the supernatant was
then analysed by HPLC-MS/MS to detect the parent compound.
CYP450 inhibition assay
The compounds originally dissolved in DMSO were added to PBS to give a
resulting concentration of 10 mM. CYP baculosomes containing cDNA for a
single human P450 isozyme, the fluorogenic substrate and the NADPH
were added to the test solution. The reaction was incubated at 378C for
at least 1 h. Fluorogenic substrates metabolized by CYP enzymes result
in highly fluorescent products in aqueous solution. The inhibition of CYP
prevents this metabolism, which corresponds to a decrease in the fluores-
cence signal. The fluorescence was measured on a plate reader.
Madin–Darby canine kidney (MDCK) cells/cell
permeability assay
The compounds were dissolved in 100% DMSO to provide 10 mM stock
solutions from which donor (dose) solutions were prepared in DMEM to
give a final drug concentration of 10 mM. All dose solutions contained
10 mM propranolol as an internal standard. MDCK cells carrying the
MDR-1 gene were used to seed filters that were exposed to a fixed volume
of the donor solution containing the compound of interest. The com-
pound’s ability to traverse the monolayer and appear in the receiver com-
partment was measured over a 30 min period. Bidirectional permeability
measurements were derived by examining the transfer of compound from
both the apical to the basolateral compartment and vice versa. Sample
analysis was conducted using LC-MS/MS with the detection settings
optimized for each test compound.
Purification of recombinant Mtb-MurE and HPLC
inhibition assay
The MurE (Rv2158c) protein of M. tuberculosis H37Rv was overexpressed
using a pVLT31 construct on Pseudomonas putida KT2442.18 A seed cul-
ture (10 mL) was prepared in LB broth containing 10 mg/L of rifampicin
and 12.5 mg/L of tetracycline. After overnight incubation at 378C and
200 rpm shaking, the seed culture was used to inoculate 1 L of LB broth
containing 12.5 mg/L of tetracycline. The culture was incubated at 308C
and 200 rpm until the OD600 reached 0.6, and was then induced with
IPTG at a final concentration of 1 mM. The culture was incubated for a fur-
ther 16 h at 308C and 200 rpm and then centrifuged at 6000 rpm for
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20 min at 48C. The pellet was resuspended in 20 mL of buffer [20 mM
Tris-HCl (pH 8.0)/300 mM NaCl] containing a protease inhibitor cocktail
(Roche). The suspension was sonicated on ice (20 cycles of 10 mm ampli-
tude for 45 s with cooling intervals on ice for 30 s) and then centrifuged at
12000 rpm for 40 min at 48C. The supernatant was loaded into an
Ni2+-NTA column equilibrated with buffer and fractions were eluted with
buffer containing increasing concentrations of imidazole (25 mM to
200 mM). Pure Mtb-MurE protein was recovered in the 200 mM imidazole
fraction as revealed by 12% SDS-PAGE analysis. The recombinant protein
was concentrated and imidazole was removed by ultrafiltration with a
10 KDa cut-off size (Spin-X UF, Corning). The HPLC inhibition assay was per-
formed as previously described.21 Briefly, the compounds were dissolved
in DMSO at a concentration of 25 mM and dilutions were prepared at
8.33 and 2.78 mM. Volumes of 2 mL of these stock compounds and 2 mL
of diluted protein (34 mg/L) were added into a 0.5 mL microfuge tube.
The substrate mixture was prepared as an aqueous solution containing
25 mM Bis-Tris-propane pH 8.5 buffer, 5 mM MgCl2, 100 mM UDP-
MurNAc-L-Ala-D-Glu, 250 mM ATP and 1 mM m-DAP, and 46 mL of this solu-
tion was dispensed into each microfuge tube. The reaction mixtures were
incubated at 378C for 30 min and the protein was then denatured by boiling
the mixture at 1008C for 10 min using a heating block. The solutions were
centrifuged for 1 min at 4000 rpm and the contents were transferred into
200 mL glass inserts fitted into 2 mL HPLC vials. A mobile phase of 50 mM
ammonium formate pH 4.0 was used for the HPLC separation of the sub-
strate and product of the enzymatic reaction eluting at a flow rate of
0.5 mL/min. The column used was an octadecylsilane Jones RP-18
(4.6 mm×250 mm×5 mm) plugged to an Agilent 1100 series HPLC
machine. The detector used was a diode array system measuring the
absorbance at 220 and 268 nm. Controls with and without recombinant
enzyme were included.
Acid-fast staining of M. bovis BCG treated with
D-cycloserine and compound 39
Early exponential-phase Middlebrook 7H9 cultures of M. bovis BCG
(OD600¼0.4) growing in a volume of 100 mL in rolling bottles at 2 rpm
and 378C were treated with 4×MIC of D-cycloserine (MIC¼25 mg/L) and
compound 39 (MIC¼40 mg/L). A control treated with DMSO was included
in the experiments. After 2 days of incubation, an aliquot of 100 mL of each
sample was dispersed onto a glass slide and dried at 1008C for 10 min. The
slide was stained with a Tb-color staining kit (Merck) and observed under a
microscope using an oil immersion lens at a magnification of×1000.
Field alignment of active molecules
The chemical structures of 3-methoxynordomesticine, leucoxine (1), 28
and 35 were drawn in Chemdraw and converted into Mol2 formats.
FieldView tool (Cresset software) was used to check the stereochemistry
and to calculate the Wildman–Crippen partition coefficient (WCLogP)
and total polar surface area. The structures were minimized at a virtual
pH of 7.0 and modelled with FieldTemplater (Cresset software) using the
default parameters to find the shared three-dimensional patterns of
these four molecules based on shape and field similarities.29 The high-
ranked conformations were used for comparing the similarities between
the four molecules.
Results
Natural product identification
Compound 1 showed a molecular ion [M+H]+ of 356.1498 m/z in
HRMS, corresponding to a molecular formula of C20H22NO5 (calc.
356.1498). A fragment at 325.1075 m/z was observed and attrib-
uted to the loss of methylamine, which is a typical feature of
aporphine alkaloids with substituents N-CH3.
30 Twenty signals
appeared in the 13C-NMR, and in conjunction with the distortionless
enhanced polarization transfer (DEPT) experiments they were
assigned to 12 aromatic sp2 carbons, three methyls, four methy-
lenes and one aliphatic methine at 61.9 ppm. There were 10 qua-
ternary carbons in total. In the 1H-NMR spectrum, singlet signals of
two aromatic hydrogens were observed at 7.30 (1H, s) and 6.54
(1H, s). In addition, two hydrogens at 6.08 (1H, d, J¼1.3 Hz) and
5.92 ppm (1H, d, J¼1.3 Hz) correlated in the HMQC spectrum
with the signal at 100.6 ppm and were assigned to the methylene-
dioxy group. Three methyl singlet signals appeared at 3.94, 3.48
and 2.58 ppm, the latter having the typical chemical shift of
N-CH3. The other aliphatic signals had d ppm values of 3.54 (1H,
dd, J¼14.4 and 4.6 Hz), 3.19–3.03 (3H, m), 2.63 (1H, dd, J¼15.7
and 3.1 Hz), 2.52 (1H, td, J¼11.8 and 3.7 Hz) and 2.25 (1H, t,
J¼14.4 Hz). The spectroscopic experimental data were in complete
agreement with the reported data for the known alkaloid leucox-
ine.31 The specific rotation of the aporphine had a positive value
([a]D
25¼+58.3, c 0.09, MeOH), as is the case in aporphines with
an (S) in configuration atC-6a.32 Compound 1 was therefore identi-
fied as (S)-leucoxine.
Synthesis
Initially, we employed the biomimetic Pictet–Spengler reaction
conditions to synthesize a first generation of over 20 THIs 2–24
decorated with a variety of substituents (Table 1) at positions
C-1, C-3, C-4, C-6 and C-7 of the THI moiety. The decision was
then made to focus on the production of THIs with aromatic or
benzylic substituents at C-1 since this feature is common to
many bioactive THI natural products such as berberines, apor-
phines and benzylisoquinoline alkaloids. Most aldehyde and
amine substrates required for the reaction were obtained from
commercial sources, apart from the phenylacetaldehydes for
the synthesis of 2, 17–21, which were produced under mild
Parikh–Doering oxidation conditions.24,33 Preparation of the com-
mercially unavailable amines (for the synthesis of compounds 15
and 16) was carried out via standard reduction reactions as pre-
viously reported.24,33 The synthesis of compounds 2–16 was per-
formed as previously described using biomimetic Pictet–Spengler
condensation,24 and 17–24 were synthesized using the same
method, with a 48%–95% yield. The reaction generally yielded
racemic products that were not resolved. However, the condensa-
tion of optically active amines or aldehydes resulted in the produc-
tion of diastereomeric mixtures that could in some cases be
separated using preparative HPLC, resulting in the optically
enriched compounds indicated (only for compounds 10 and 11).
Following the MIC data from this first generation of synthetic
THIs, a second series of 11 novel compounds 25–35 with struc-
tures centred on scaffolds possessing 3,4-methylenedioxybenzyl
and 2,3-methylenedioxyphenyl moieties were prepared from the
corresponding aldehydes A and B (Table 2). Variations on each of
the positions of the THI ring were investigated, with functionalities
including methyl, carboxyl, hydroxyl and halogen substituents.
The Pictet–Spengler condensation reaction is known to be mainly
para-directing due to the electron-donating group at C-6.
However, this para-directed cyclization is mechanistically not pos-
sible if a substituent is present at C-9. In this case, and as we
observed for 28 and 35, the cyclization can only proceed ortho
to the electron-donating group and leads to the 5,8-disubstituted
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Table 1. Phosphate-mediated Pictet–Spengler condensation of phenethylamines with aldehydes to give the first-generation THIs24,42
R6
R4
R3R6
R7
2–24
1
R4
R3 H O 0.1 M K2HPO4
pH 6, 50 °CR1
+
R7
NH2
R1
NH
THI product R1 R3 R4 R6 R7 Yield (%)
2 CH2(4-HOC6H4) H H OH OH 63
3 CH2C6H5 H H OH OH 73
4 2-Pyridyl H H OH OH 77
5 4-MeOC6H4 H H OH OH 31
6 4-HOC6H4 H H OH OH 35
7 3-HOC6H4 H H OH OH 80
8 2-HOC6H4 H H OH OH 86
9 2-Thienyl H H OH OH 79
10 (1S)-CH2C6H5 H (4R)-OH OH OH 27
11 (1R)-CH2C6H5 (3S)-CO2H H OH OH 30
12 4-Isoquinolyl H H OH OH 88
13 (1RS,2′S)-2′,6′-dimethylhept-5′-enyl H H OH OH 43
14 (1R,1′S)-1′,2′-dihydroxyethyl H H OH OH 68
15 CH2C6H5 H H NH2 H 52
16 CH2C6H5 H H OH H 74
17 CH2(3-HOC6H4) H H OH OH 48
18 CH2(3,4-MeOC6H3) H H OH OH 76
19 CH2(3-MeO,4-HOC6H3) H H OH OH 49
20 CH2(3,4-OCH2OC6H3) H H OH OH 80
21 CH2(2-BrC6H4) H H OH OH 95
22 1-CH3,1-CO2H H H OH OH 52
23 cyclohexyl H H OH OH 91
24 C9H19 H H OH OH 90
Table 2. Phosphate-mediated Pictet–Spengler condensation of phenethylamines with aldehydes to give the second series of THIs (25–35)
R6
R5
R2 H
A
B
25–28 29–35
or
O
R4
R3 0.1 M K2HPO4
pH 6, 50 °C
+
R7
R8
HN
R6
R5
R2
R4
R3
R7
R8
O
O
O
H O
O N
R6
R5 R4
R2
R3
R7
R8
N
O
O
OO
THI product Aldehyde used R2 R3 R4 R5 R6 R7 R8 Yield (%)
25 A H (3S)-CH3 (4R)-OH H OH H H 93
26 A H (3S)-CO2H H H OH OH H 96
27 A H H H H OH H H 27
28 A H H H Br H H OH 8
29 B H H H H OH OH H 99
30 B H H (4R)-OH H OH OH H 84
31 (1R) B CH3 H (4R)-OH H OH OH H 57
32 (1S) B CH3 H (4R)-OH H OH OH H 38
33 B H H H H OH OH OH 29
34 B H H H H OH H H 92
35 B H H H Br H H OH 17
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THIs. Ortho-cyclization under our biomimetic reaction conditions
resulted in the formation of products 28 and 35 at low yields. This
is likely to result from steric hindrance around the newly formed
carbon–carbon bond as well as competition with undesired side
reactions.
The C-5, C-8 disubstituted THIs 28 and 35 displayed good MIC
values and prompted us to further investigate close structural ana-
logues of 28. Since the biomimetic reaction conditions gave the
products in low yield, albeit in one step, the alternative Bischler–
Napieralski strategy for the synthesis of a third generation of com-
pounds 36–40 was investigated (Figure 1 and Table 3).
Initially, halogenated phenethylamines were prepared via either
the chlorination or iodination, using N-chlorosuccinimide (NCS) or
N-iodosuccinimide (NIS), of 3-methoxyphenylacetonitrile, and sub-
sequent reduction using borane. 2-(2-Bromo-5-methoxyphenyl)
ethylamine was prepared as previously described.34 Coupling with
3,4-(methylenedioxy)phenylacetic acid produced the desired
2-halo-5-hydroxyamides, which were used in ortho-directed
Bischler–Napieralski condensation reactions to give the corre-
sponding halogenated THIs (36, 37 and 38) in moderate yields.
Further modifications included the regioselective bromination of
37 using N-bromosuccinimide (NBS) at the C-6′ position of the
3′,4′-methylenedioxylbenzyl substituent, to give 39 in a 35% yield.
In addition, reduction of the bromide 37 gave 40 in an 89% yield.
Anti-TB activity, eukaryotic cell toxicity and
pharmacokinetic analysis
Compound 1 was found to inhibit the growth of M. bovis BCG and
M. tuberculosis H37Rv with an MIC of 25 and 30 mg/L, respectively
(Table 4), and exhibited low cytotoxicity with a GIC50 value of
125 mg/L. The SI against M. tuberculosis was calculated to be
4.17 (not shown in Table 4), which indicates that it is four times
as specific towards the pathogen than it is towards murine macro-
phage cells.
The first generation of synthetic 1-substituted THIs (2–24)
aimed to identify functionalities possessing bioactivity (Figure 2).
Norcoclaurine (2) did not show significant anti-TB activity (MIC
.100 mg/L for M. bovis BCG). Most of the compounds from the
first generation were also unsuccessful in inhibiting the growth of
slow-growing M. bovis BCG at 100 mg/L. However, five compounds
(10, 13, 16, 20 and 24) inhibited the growth of the bacilli with MIC
values.60 mg/L. 1-Benzyl-substituted 6,7-dihydroxy THI 10 bearing
a hydroxyl group C-4 was active at 100 mg/L and showed low cyto-
toxicity with a GIC50 .250 mg/L. The 1-(1,2-dihydronorgeranyl)-
substituted 6,7-dihydroxy THI 13, 1-benzyl-substituted 6-hydroxy
THI 16 and 1-methylenedioxybenzyl-substituted 6,7-dihydroxy THI
20 also displayed an MIC value of 100 mg/L. Moreover, the
1-nonane-substituted 6,7-dihydroxy THI 24 showed an MIC of 80
and 60 mg/L for M. tuberculosis H37Rv and M. bovis BCG, respectively;
however, this compound was found to be highly cytotoxic towards
macrophages, with a GIC50 value of only 1.6 mg/L.
The second-generation compound 3′,4′-methylenedioxybenzyl
THI 27, with a 6-hydroxy substitution, inhibited M. bovis BCG
at 100 mg/L with moderate cytotoxicity (RAW264.7 GIC50
150 mg/L), achieving an SI value of 1.5. It is noteworthy that the
presence of 5-bromo-8-hydroxy substitution (28 and 35) conferred
a considerable increase in anti-TB potency over the basic THI
scaffold. Indeed, 3′,4′-methylenedioxybenzyl 28 and 2′,3′-methy-
lenedioxyphenyl 35 THIs had respective MIC values of 20 and
60 mg/L for M. bovis BCG. The SIs were ≥2 for both compounds,
suggesting that specificity could be achieved by the 5-bromo-8-
hydroxy substitution on the ring. Other THIs from the second
generation were less active (MIC .100 mg/L), and surprisingly
the 6,7,8-trihydroxy-2′,3′-methylenedioxyphenyl THI 33 was
found to be highly toxic to the macrophages, with a GIC50 of
5.5 mg/L.
The third generation of THIs (36–40) was based on the most
selective hit from the second generation, the 5-bromo-8-
hydroxy-3′,4′-methylenedioxybenzyl THI 28. The introduction of
a methoxyl substitution to position 8 (in 37) instead of the
CN
OMe dOMe
X
X
MeO
NH2
MeO
X
OMe
NH2
c
X = Br
36 (X = Cl)
37 (X = Br)
38 (X = I)
a, b
X = Cl, I
h
NH
O g
e, f
O
O
O
MeO
NH 40
39
O
O
Cl
MeO
NH
O
OBr
HN
O
X = Cl, Br, I
Figure 1. Bischler–Napieralski-mediated synthesis to ortho-cyclized
THIs 36–40. (a) NCS or NIS, CH2Cl2; 85% and 81% yield, respectively;
(b) For X¼Cl and I, B2H6.SMe2, 42% and 55%, respectively. (c) Br2,
CH3CO2H, 67%. (d) 3,4-(Methylenedioxy)phenylethanoic acid, N,N-
dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine (DMAP),
CH2Cl2; X¼Cl and X¼Br, 99%, X¼ I, 74%. (e) POCl3, toluene, reflux. (f)
NaBH3CN, MeOH; 36 19%, 37 19%, 38 2% over two steps. (g) 36, NBS,
CH2Cl2, 35%. (h) 37, LiAlH4, –788C, 89%.
Table 3. Third-generation THIs (36–40)
R8
R9
R5
NH 36–40
O
O
THI product R5 R8 R9
36 Cl OMe H
37 Br OMe H
38 I OMe H
39 Cl OMe Br
40 H OMe H
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phenolic hydroxyl (in 28) retained the anti-TB activity with an MIC
value of 40 and 30 mg/L for M. tuberculosis H37Rv and M. bovis
BCG, respectively. However, the compound was much more cyto-
toxic, with a GIC50 of 30 mg/L, and the selectivity was lost.
Replacing the 5-bromo substitution of 8-methoxylated 37 for
other halogens (chloro in 36 and iodo in 38) did not change its bio-
logical profile, both being cytotoxic. Interestingly, a THI containing
a 5′-bromo in ring C but conserving the same substitution of the
Table 4. MICs for two different species of slow-growing mycobacteria, the GIC50 for the murine macrophage cell line RAW264.7 and the SIs of natural
and synthetic compounds 1-40
Name or code
MIC (mg/L) [mM]
GIC50 RAW264.7 (mg/L) [mM] SI (¼GIC50/MIC) Mtb-MurE HPLC IC50 (mM)M. bovis BCG M. tuberculosis H37Rv
(S)-Leucoxine (1) 25 [70] 30 [84] 125 [352] 5.0 820
Norcoclaurine (2) .100 [.369] ND 425 [1566] ,4.3 837
3 .100 [.392] ND 81 [313] ,0.81 ND
4 .100 [.413] ND 60 [248] ,0.60 ND
5 .100 [.369] ND 91 [335] ,0.91 ND
6 .100 [.389] ND 92 [358] ,0.92 ND
7 .100 [.389] ND 88 [342] ,0.88 ND
8 .100 [.389] ND 87 [338] ,0.87 ND
9 .100 [.404] ND 56 [226] .0.56 ND
10 100 [271] ND .250 [.566] .2.5 ND
11 .100 [.334] ND 87 [291] ,0.87 ND
12 .100 [.342] ND .250 [.855] ND ND
13 100 [346] ND .250 [.864] .2.5 ND
14 .100 [.444] ND 85 [377] ,0.85 ND
15 .100 [.420] ND 188 [789] ,1.9 ND
16 100 [418] ND 195 [683] 2.0 ND
17 .100 [.369] ND 64 [236] ,0.64 ND
18 .100 [.317] ND 56 [178] ,0.56 ND
19 .100 [.332] ND 50 [166] ,0.50 ND
20 100 [334] ND 190 [602] 1.9 237
21 .100 [.299] ND 47 [141] ,0.47 ND
22 .100 [.448] ND 178 [797] ,1.8 ND
23 .100 [.404] .100 [.404] 45 [182] ,0.45 ND
24 80 [275] 60 [206] 1.6 [5.5] 0.02 186
25 .100 [.319] ND 181 [578] ,1.8 ND
26 .100 [.291] ND 183 [533] ,1.8 ND
27 100 [353] ND 150 [529] 1.5 .1000
28 20 [55] ND 47 [130] 2.3 ,111
29 .100 [.351] ND 75 [263] ,0.75 471
30 .100 [.332] ND 89 [295] ,0.89 ND
31 .100 [.317] ND 137 [434] ,1.4 ND
32 .100 [.317] ND 181 [574] ,1.8 ND
33 .100 [.332] ND 5.5 [18] ,0.055 148
34 .100 [.371] ND 181 [672] ,1.8 .1000
35 60 [172] ND 121 [348] 2.0 ,111
36 40 [121] 60 [181] 41 [124] 1.0 ND
37 20 [53] 40 [106] 30 [80] 1.5 165
38 50 [118] 30 [71] 28 [66] 0.56 ,111
39 40 [97] 40 [97] 73 [178] 1.8 ND
40 .50 [.168] .100 [.336] 220 [740] ,4.4 300
Isoniazid 0.1 [0.73] 0.1 [0.73] 3000a 30000 .1000
Rifampicin 0.05 [0.061] 0.05 [0.061] 700a 14000 ND
Enzymatic IC50 values for MurE of M. tuberculosis were established by HPLC for selected compounds. Isoniazid and rifampicin were included as positive
controls. The MIC and IC50 of compounds that were not tested are indicated as not determined (ND).
aValue taken from Gupta and Bhakta.27
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THI nucleus as in 37 resulted in compound 39, which was
active (MIC 40 mg/L) and less toxic than the parent 37 (Table 3).
The 40 derivative bearing both the 8-methoxy and the
3′,4′-methylenedioxybenzyl substitution was inactive, confirming
the importance of the halogen substitution on anti-TB activity.
Antibacterial specificity
As the yield of the best performing THIs (28 and 35) was
extremely low, three representative compounds (20, 24 and 36)
with modest antimycobacterial property and higher yields were
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Figure 2. Chemical structures of the natural aporphines 3-methoxynordomesticine and (S)-leucoxine (1) and the synthetic THIs 2-40. Compounds 1-40
were evaluated in this study.
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evaluated against alternative bacterial species for their antibac-
terial specificity. Two rapid-growing mycobacterial species,
M. smegmatis mc2155 and M. aurum, the acid-fast bacterium
R. equi RHA1 and two Gram-negative bacteria, E. coli and P. putida,
were screened using the SPOTi assay. The three THIs were
completely inactive against both Gram-negative species (MIC
.100 mg/L) and the acid-fast bacterium R. equi RHA1 (MIC
.100 mg/L) (Table 5). THI 20 did not inhibit M. aurum or M. smeg-
matis mc2155 at 100 mg/L; however, 24 inhibited both M. aurum
and M. smegmatis mc2155 at 100 mg/L, and 36 inhibited both
rapid-growing mycobacterial species at 60 mg/L.
Absorption, distribution, metabolism and excretion
analysis
Compounds 28 and 35were selected for pharmacokinetic/pharma-
codynamic profiling on the basis of their potent antimycobacterial
property and modest SI values (Supplementary data). The hepato-
cyte stability assay showed both 28 and 35 to have a high hepatic
extraction ratios of .0.6. However, the t1/2 of 28 (23.17 min) in
human hepatocytes was much shorter than that of 35 at
78.6 min (Table 6). This trend continued with the microsomal stabil-
ity studies, with 28 shown to have a t1/2 of 9.81 min, 10-fold shorter
than that of 35. Both compounds showed encouraging solubility
(35, 0.3 mg/mL; 28, 0.8 mg/mL). Membrane permeability revealed
compound 35 to be moderately permeable in the MDCK monolayer
assay (3.2×10– 6 cm/s) while compound 28 was marginally less
permeable (1.7×10–6 cm/s). Inspection of the efflux permeability
ratios suggested that both compounds were P-glycoprotein sub-
strates, and metabolic turnover in both microsomes and hepato-
cytes confirmed both compounds to be highly metabolized.
MurE synthetase inhibitory properties
Thirteen compounds were tested for their enzymatic inhibition of
the MurE synthetase of M. tuberculosis using the previously
reported HPLC assay.21 Isoniazid was employed as a negative con-
trol, showing no inhibitory effect at any of the concentrations
examined. IC50 values were calculated by interpolation of the
discrete inhibitory percentage data based on the AUCs of
the UDP-MurNAc-L-Ala-g-D-Glu-m-DAP product (Table 4). Three
compounds (28, 35 and 38) demonstrated particularly effective
MurE inhibition, with IC50 values ,111 mM. Six others (20, 24,
29, 33, 37 and 40) had a range of IC50 values between 111 mM
and 500 mM, while the natural product (S)-leucoxine (1) and syn-
thetic norcoclaurine (2) showed IC50 values 830 mM. Only two
THIs exhibited no enzymatic inhibitory effect (IC50.1 mM).
Interestingly, compounds bearing a halogen atom at C-5 of the
THI nucleus such as 28, 35, 37 and 38 were all inhibitory to the
MurE ligase, with IC50,200 mM. A positive trend (r¼0.549)
between the enzymatic inhibition of Mtb-MurE (IC50) and the
growth inhibition of M. tuberculosis H37Rv (MIC) was observed for
eight THIs, which had IC50 and MIC values in the range 40–
400 mM. The linear fit of the experimental data had a slope of
0.544 and a y-intercept of 92.12 mM. The t-test reported P,0.1,
indicating that there was a weak relationship between the two
variables.
Field alignment of active molecules
The alignment of 3-methoxynordomesticine, leucoxine (1), 28
and 35 showed that the four molecules generated a similar three-
dimensional distribution of the electrostatic, lipophilic and van der
Waals fields (Figure 3). Even in cases where the chemical groups
did not exactly match [for instance, the methylenedioxy substi-
tuted ring is oriented in a different direction in leucoxine (1) com-
pared with 3-methoxynordomesticine, 28 and 35], the fields
generated were spatially concurrent. The score obtained in the
alignment of these four molecules (FieldTemplater global score
0.689) suggested that these four molecules created a similar
three-dimensional environment around them.
Phenotype analysis
Liquid M. bovis BCG cultures treated at an early exponential phase
with 4×MIC concentrations of D-cycloserine (100 mg/L) and of
39 (160 mg/L) showed a distinct cellular phenotype in the
Table 5. MICs of three THIs for two rapid-growing mycobacterial species (M. aurum and M. smegmatis), an acid-fast bacterium R. equi (RHA1) and two
Gram-negative bacteria (E. coli and P. putida)
Compound
MIC (mg/L)
M. aurum M. smegmatis mc2155 R. equi RHA1 E. coli K12 P. putida
20 .100 .100 .100 .100 .100
24 100 100 .100 .100 .100
36 60 60 .100 .100 .100
Rifampicin 0.1 0.1 ND ND ND
Kanamycin ND ND 1 1 10
ND, not determined.
Table 6. Microsomal and hepatocytic stability of compounds 28 and 35
Compound
t1/2 (min)
CLint (mL/min/million cells)microsomes hepatocytes
28 9.8 23.2 17.4
35 109.6 78.6 12.6
The t1/2 of both compounds in hepatocytes and microsomes was
determined and their in vivo hepatic intrinsic clearance (CLint) prediction
values are shown.
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microscopic acid-fast staining observation (Figure 4). Cells treated
with either D-cycloserine or 39 were significantly longer than the
control treated with the vehicle (DMSO). The untreated control
showed a cell length of 2.7+0.5 mm, while cells treated
with D-cycloserine had a much longer length of 4.2+1.0 mm.
A similar elongation was observed with 39, showing a length of
4.7+1.4 mm. The mean cell sizes of the three treatments were
statistically significant with P,0.01 by analysis of variance.
Discussion
(S)-Leucoxine (1) isolated from Rhodostemonodaphne crenaticupula
Madrin˜an was found to completely inhibit the growth of M. bovis
BCG and M. tuberculosis H37Rv at around 25–30 mg/L. The substitu-
tion of this aporphine alkaloid was similar to that of the previously
reported hit 3-methoxynordomesticine.13 However, 1was less cyto-
toxic with an SI of 4 while the SI of 3-methoxynordomesticine was
around 1. This result indicated that interchanging the chemical sub-
stitutions from rings A to D had an insignificant effect on the com-
pound’s anti-TB activity but a considerable effect on the eukaryotic
cell toxicity. (-)-Nordicentrine, which has a methylenedioxy group on
ring A and a dimethoxy substitution on ring D, has been reported to
have an MICvalue of 12.5 mg/L for the virulentM. tuberculosisH37Rv
strain, also being cytotoxic against cancer cell lines.12
Among the first generation of THIs (2–24), several interesting
structure–activity relationships were extracted from the whole-cell
biological data. By comparing the structures and MIC values of 3
and 16, it was noted that a single hydroxyl at C-6 (as in 16) resulted
in inhibition at 100 mg/L while the presence of a dihydroxy substi-
tution at C-6 and C-7 (as in 3) did not lead to inhibition at the same
concentration. The presence of a hydroxyl group at C-4 of the
6,7-dihydroxy-substituted-THI nucleus in compound 10 also
conferred growth-inhibitory activity at 100 mg/L. Moreover,
the presence of a lipophilic chain at C-1 of the 6,7-dihydroxy
substituted-THIs (in 13 and 24) showed a tendency for an increase
in the mycobacterial inhibitory properties. A differential effect in
terms of cytotoxicity was observed between these compounds,
with the 1,2-dihydronorgeranyl-substituted THI (13) being far less
cytotoxic than the nonane-substituted THI (24), perhaps due to the
greater surfactant-like properties of 24. It was interesting to
observe that the 1-(3′,4′-methylenedioxybenzyl)-6,7-dihydroxy
THI (20), which is the compound most structurally similar to
3-methoxynordomesticine, was able to inhibit mycobacterial growth
at 100 mg/L, suggesting that the 3′,4′-methylenedioxybenzyl substi-
tution conferred anti-TB activity compared with other benzyl
substitutions.
The second generation of compounds (25-35) shared either
the 3′,4′-methylenedioxybenzyl substitution (25-28) or the
2′,3′-methylenedioxyphenyl substitution (29-35). As mentioned
earlier, the 5-bromo-8-hydroxy substitution (in both 28 and 35)
undoubtedly conferred marked anti-TB activity. It still remains
to be fully elucidated whether the halogen or the hydroxyl
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Figure 4. Acid fast staining of M. bovis BCG after 48 h of treatment with
D-cycloserine (DCS) and 39, and comparison of the cell length. (a)
Control with DMSO. (b) DCS at 100 mg/L. (c) Compound 39 at 160 mg/L.
Magnification×1000. (d) The cell length of M. bovis BCG after treatment
with vehicle (DMSO), DCS (100 mg/L) and 39 (160 mg/L). The dots
represent the raw data and the diamonds represent the mean value
with SD (error bars). The cell length of 100 cells was manually measured
for each treatment from microscopic images. The mean cell sizes of the
three treatments were statistically significant at P,0.01. This figure
appears in colour in the online version of JAC and in black and white in
the print version of JAC.
3-Methoxynordomesticine
0.12 0.12
0.12 0.12
Leucoxine (1)
28 35
Figure 3. Comparison of the three-dimensional surface of four
active alkaloids using FieldTemplater (Cresset software). Alignment of
3-methoxynordomesticine, leucoxine (1), 28 and 35 showing surfaces of
different chemical environments. Turquoise surfaces represent negative
patches, red surfaces correspond to positive sections, brick yellow
surfaces denote lipophilic regions and light yellow volumes relate to
dominant van der Waals areas. This figure appears in colour in the
online version of JAC and in black and white in the print version of JAC.
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substitution is responsible for the activity of these entities, as
removal of the halogen or methylation of the hydroxyl in the third-
generation compounds led to lower anti-TB activities. The benzyl
derivative (28) was three times more active than the phenyl
derivative (35), probably because of the increased conformational
flexibility of the former, which could influence binding to the
molecular target. In general, the benzylic derivatives seem more
promising than the phenyl derivatives. As observed for 16, the sin-
gle phenolic group at C-6 of 27 was deemed important for retain-
ing the anti-TB activity, although derivatization at this position has
yet to be explored.
Pharmacokinetic/pharmacodynamic analyses showed that 28
had a high aqueous solubility, probably translating to a more
hydrophilic nature, which would explain its lower cellular perme-
ability compared with 35. In addition, 28 demonstrated higher
instability in both hepatocytes and microsomes, meaning that
it was metabolized rapidly and had low retention times. It
also inhibited the activity of CYP450 enzymes to a greater
extent than 35. As both 28 and 35 were found to be substrates
for P-glycoprotein efflux mechanisms, the use of these com-
pounds in combination with existing, potent efflux pump inhibi-
tors could result in a significantly enhancement of their anti-TB
properties.
The study of anti-TB properties of the third generation (36–40)
of compounds indicated that the presence of bromine at C-5 led
to a greater inhibitory potency compared with the chloro- or
iodo-analogues. It is probable that size and the electronegativity
of the bromine atom contribute favourably to optimal contact
with the target macromolecule. In addition, when comparing
36–38 with 35, it was clear that the 8-methoxy derivatives
were much more toxic than the 8-hydroxy compound 35 (without
a significant gain in antimycobacterial activity). Interestingly, a
further substitution with a bromo group at 2′ on the benzyl ring
reduced the cytotoxicity while maintaining effective mycobacter-
ial killing. This is possibly due to conformational or steric effects
induced by the presence of a halogen.35
The synthetic THIs were equally active against other environmen-
tal species of mycobacteria such as M. smegmatis and M. aurum;
however, they were not growth inhibitors of Gram-negative bacteria
such as E. coli or P. putida, or acid-fast Rhodococcus equi RHA1. The
mycobacterial specificity of this class was previously demonstrated
by us for 3-methoxynordomesticine13 and seems to suggest that
the class inhibits a specific endogenous mechanism particular to
Mycobacterium.
Among the 13 compounds examined for inhibition of Mtb-MurE
activity, 11 compounds showed enzymatic inhibition, three of
which had IC50 values ,111 mM. It seems reasonable that the
aporphines13 and THIs share a common pharmacophore, which
inhibits Mtb-MurE ligase. According to the computational field
alignment of the molecules, the key structural motif seems to be
the presence of dissimilar pairs of electrostatically positive patches
(in red in Figure 3), caused by the nitrogen atoms and the relative
spatial closeness of the methylenedioxy groups. The presence of
halogens in position 5 of the isoquinoline nucleus clearly increased
Mtb-MurE inhibitory activity. For instance, 40 showed an Mtb-MurE
IC50 value of 300 mM whereas those compounds with halogens dis-
played an Mtb-MurE IC50 value,170 mM. The effect appears to be
more pronounced with larger halogens such as bromine and iodine
(35 and 38) in comparison with chlorine (36). A phenolic substitu-
tion in position 8 of the isoquinoline nucleus also conferred
increased Mtb-MurE inhibition (as seen by a comparison of the
Mtb-MurE IC50 for compounds 29 and 33).
There is a positive trend between the inhibition of Mtb-MurE
(IC50) and the anti-TB activity (MIC), as evidenced by the plot cor-
relating the two variables. An increase in Mtb-MurE IC50 is asso-
ciated with an increase in the whole-cell MIC, suggesting that
MurE inhibition contributes to the antimicrobial effect observed
for this class. However, the correlation is weak as the t-test sug-
gests there is 1 in 10 probability that this observation occurs by
chance. This potentially indicates that there could be other poten-
tial molecular targets involved in the phenotypic inhibitory effect
of the THIs.
Mycobacterial cells treated with 4×MIC concentrations of
compound 39 or D-cycloserine showed significant morphological
cellular elongation when compared with the control treatment
(Figure 4). It is well known that D-cycloserine inhibits both
D-alanine racemase and D-alanine:D-alanine ligase in M. tubercu-
losis,36,37 essential enzymes for the biosynthesis of the D-alanine
optical isomer and its dimer, which are ultimately required for
building the cytoplasmic PG precursor UDP-MurNAc-L-Ala-g-D-
Glu-m-DAP-D-Ala-D-Ala. Treatment with other inhibitors of PG bio-
synthesis such as vancomycin and cephalosporin C also results in
elongated cells (J. D. Guzman, A. Maitra and S. Bhakta, unpub-
lished data). This elongated phenotype has been observed in
mycobacterial cells overexpressing or depleting serine/threonine
kinases PknA/B38 or overexpressing the cell-division suppressor
Rv2719c,39 proteins that are associated with the regulation of
PG biosynthesis and recycling. It is well established that
filamentous-shaped bacteria (another term for elongated cells)
typically appear as a consequence of an interruption in cell div-
ision40 and it is therefore not surprising that drugs affecting PG
biosynthesis provoke this phenotype. Although drugs targeting
other pathways can also arrest cell division and lead to cell elong-
ation (for instance, quinolones also elongate the cells),40,41 the
observed phenotype is consistent with an unbalanced cell wall
assembly, a feature that could be explained by an inhibition of
ATP-dependent Mur ligases. This hypothesis is favoured by our
experimental data; however, further investigation of the molecu-
lar mechanism(s) of action is needed, which may ultimately boost
chemical design efforts to develop a successful anti-TB scaffold.
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